Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of ...
Frontiers in Oncology has retracted a 2024 paper on sorafenib combined with tarexib for unresectable hepatocellular carcinoma ...
A new research paper titled "A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850" has been published in Oncotarget. Overexpression of metabotropic glutamate ...
Chemoresistant hepatoblastoma (HB) is associated with poor outcomes. Cyclin-dependent kinases (CDKs) are potential therapeutic targets because of their critical role in cell growth and chemoresistance ...
Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with ...
Sorafenib is an oral multitargeted tyrosine kinase inhibitor with potent antiangiogenic activity. It was first approved to treat renal-cell carcinoma, 1 but it is also active in other solid tumors, ...
The diagnosis and treatment of hepatocellular carcinoma (HCC) constitute a complex and challenging clinical paradigm. The diagnosis and treatment of hepatocellular carcinoma (HCC) constitute a complex ...
The median overall survival was 16.5 months with anlotinib plus penpulimab and 13.2 months with sorafenib. First-line treatment with anlotinib and penpulimab can improve survival outcomes when ...
Prior to this past year, induction chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) had not changed appreciably for several decades. However, with the FDA approval of ...
WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 22, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen ...
Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved ...
Discover comprehensive details about Sorafenib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results